GB201603571D0 - Markers for skeletal disorders - Google Patents
Markers for skeletal disordersInfo
- Publication number
- GB201603571D0 GB201603571D0 GBGB1603571.9A GB201603571A GB201603571D0 GB 201603571 D0 GB201603571 D0 GB 201603571D0 GB 201603571 A GB201603571 A GB 201603571A GB 201603571 D0 GB201603571 D0 GB 201603571D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- markers
- skeletal disorders
- skeletal
- disorders
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/105—Osteoarthritis, e.g. cartilage alteration, hypertrophy of bone
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/108—Osteoporosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Rheumatology (AREA)
- Rehabilitation Therapy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1603571.9A GB201603571D0 (en) | 2016-03-01 | 2016-03-01 | Markers for skeletal disorders |
| PCT/GB2017/050546 WO2017149300A1 (en) | 2016-03-01 | 2017-03-01 | Markers for skeletal disorders |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1603571.9A GB201603571D0 (en) | 2016-03-01 | 2016-03-01 | Markers for skeletal disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB201603571D0 true GB201603571D0 (en) | 2016-04-13 |
Family
ID=55807143
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB1603571.9A Ceased GB201603571D0 (en) | 2016-03-01 | 2016-03-01 | Markers for skeletal disorders |
Country Status (2)
| Country | Link |
|---|---|
| GB (1) | GB201603571D0 (en) |
| WO (1) | WO2017149300A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240019862A (en) | 2017-09-01 | 2024-02-14 | 벤 바이오사이언시스 코포레이션 | Identification and use of glycopeptides as biomarkers for diagnosis and treatment monitoring |
| PH12021552952A1 (en) | 2019-07-12 | 2022-07-25 | Alzchem Trostberg Gmbh | Metastable crystal modification and method for the production thereof (i) |
| CN112782292B (en) * | 2020-12-21 | 2023-04-07 | 浙江大学医学院附属邵逸夫医院 | Application of metabolite ADMA in preparation of early osteoarthritis diagnosis kit |
| EP4565143A2 (en) * | 2022-08-05 | 2025-06-11 | Ochalski, Pawel G. | Leaky joint syndrome diagnostics and treatments |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050124071A1 (en) * | 2003-09-30 | 2005-06-09 | Kraus Virginia B. | Methods and compositions for diagnosing musculoskeletal, arthritic and joint disorders by biomarker dating |
| US20070148704A1 (en) * | 2005-10-06 | 2007-06-28 | Ursula Klause | Anti-CCPand antinuclear antibodies in diagnosis of rheumatoid arthritis |
| JP2010506147A (en) * | 2006-09-29 | 2010-02-25 | エフ.ホフマン−ラ ロシュ アーゲー | Risk assessment of disease progression for patients with rheumatoid arthritis |
| CA2777800C (en) * | 2009-10-15 | 2019-11-12 | Crescendo Bioscience | Biomarkers and methods for measuring and monitoring inflammatory disease activity |
| US10018591B2 (en) * | 2012-06-11 | 2018-07-10 | Preventage Healthcare, Llc | Methods for improving diabetes management |
-
2016
- 2016-03-01 GB GBGB1603571.9A patent/GB201603571D0/en not_active Ceased
-
2017
- 2017-03-01 WO PCT/GB2017/050546 patent/WO2017149300A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017149300A1 (en) | 2017-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3478217T3 (en) | Historisk scanningsreference for intraorale scanninger | |
| GB201602934D0 (en) | Compounds | |
| GB201620119D0 (en) | Compounds | |
| GB201619694D0 (en) | Compounds | |
| GB201604027D0 (en) | Compounds | |
| GB201604020D0 (en) | Compounds | |
| GB201610854D0 (en) | Compounds | |
| IL263228A (en) | Benzoxaborole compounds | |
| GB201608777D0 (en) | Compounds | |
| GB201613946D0 (en) | Compounds | |
| GB201604022D0 (en) | Compounds | |
| GB201604030D0 (en) | Compounds | |
| GB201603571D0 (en) | Markers for skeletal disorders | |
| GB201713217D0 (en) | Compounds | |
| GB201701455D0 (en) | Neurodegenerative disorders | |
| GB201621520D0 (en) | Compounds | |
| GB201622362D0 (en) | Compounds | |
| GB201604029D0 (en) | Compounds | |
| PL3601700T3 (en) | Dividing member for boiserie | |
| GB201622365D0 (en) | Compounds | |
| GB201407132D0 (en) | Marker for neurodegenerative disorders | |
| GB201604031D0 (en) | Compounds | |
| GB201712443D0 (en) | Markers | |
| GB201713179D0 (en) | Fixing Marker | |
| GB201720511D0 (en) | Compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |